600380 Joincare Pharmaceutical Group Industry
- 13.01
- -0.15-1.14%
Joincare Pharmaceutical Group Industry News
Health Source (600380.SH): Recently communicated with the Drug Evaluation Center of the State Drug Administration regarding the marketing application of TG-1000 capsules to treat influenza
Gelonghui, May 11丨Health Yuan (600380.SH) said at the performance briefing that the multi-center phase III clinical trial of TG-1000 capsules for uncomplicated acute influenza A and B infections aged 12 and above has now reached the main research end. The company will communicate with the Drug Evaluation Center (CDE) of the China Drug Administration about the marketing application of TG-1000 capsules to treat influenza in the near future to advance the marketing process of TG-1000 capsules. If there are any relevant developments in the future, the company will promptly disclose them as required.
Health Yuan (600380): Performance remains steady and the two-wheel drive strategy continues to advance
Incident: The company achieved operating income of 16.646 billion yuan in 2023, -2.90% year on year; net profit to mother of 1,443 billion yuan, -3.99% year on year; net profit after deducting non-return to mother of 1,374 billion yuan, -3.1 percent year on year
Private Companies Account for 48% of Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Ownership, While Individual Investors Account for 35%
Key Insights Joincare Pharmaceutical Group IndustryLtd's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 3 in
Health Source (600380): Performance is in line with expectations, and Tubuu is expected to accelerate its volume quarterly
Guide to this report: The collection of zoxa and budesonide caused respiratory pressure for 24 years. Tobramycin is expected to accelerate quarterly release, and salmetroticasone is expected to be approved for marketing in 24Q2, which is expected to drive positive respiratory growth and maintain an “increase in maintenance” rating. invests
Health Source (600380): 1Q24 results are in line with expectations, TG-1000 reached the main phase III clinical endpoint
1Q24 results are in line with our expectations Health Yuan announced results for the first quarter of 2024: operating income of 4.34 billion yuan, down 4.81% year on year; net profit to mother of 440 million yuan (corresponding to basic earnings per share of 0.24 million yuan
Express News | Health Source: The company's injectable cetrorelix acetate was approved by the US FDA
Health Yuan (600380.SH) announced first-quarter results, net profit of 440 million yuan, a year-on-year decrease of 4.96%
According to the Zhitong Finance App, Health Yuan (600380.SH) disclosed its report for the first quarter of 2024. During the reporting period, the company achieved revenue of 4.34 billion yuan, a year-on-year decrease of 4.81%; net profit to mother was 440 million yuan, a year-on-year decrease of 4.96%; after deducting non-net profit of 428 million yuan, a year-on-year decrease of 4.26%. Basic earnings per share were $0.2357.
Joincare Pharma Says Flu Drug Phase 3 Trial Attains Primary Endpoint
Joincare Pharmaceutical Group (SHA:600380) said its phase 3 trial for TG-1000 capsules as a treatment for influenza A and B reached the primary research endpoint, according to a Thursday filing with t
Health Source (600380.SH): TG-1000 capsule phase III clinical trial reached the main end
Gelonghui, April 17 | Health Source (600380.SH) announced that recently, the company's innovative drug product TG-1000 capsules for use in a multi-center phase III clinical trial (referred to as this study) with no complications in acute influenza A and B infections aged 12 and above (referred to as this study) reached the end of the main study. The company will communicate with the Drug Evaluation Center (CDE) of the China Drug Administration about the marketing application of TG-1000 capsules to treat influenza in the near future to advance the marketing process of TG-1000 capsules.
Some May Be Optimistic About Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Earnings
The market for Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) shares didn't move much after it posted weak earnings recently. We did some digging, and we believe the earnings are str
Health Source (600380) Company Information Update Report: Inhalation Formulation Leader's Innovative Drugs and High-Barrier Formulations Accelerate
Performance is under slight pressure. Diversified businesses are progressing together to maintain the “buy” rating. In 2023, the company achieved operating income of 16.646 billion yuan (-2.90%, the following are all year-on-year ratios); achieved net profit of 1,443 billion yuan to mother
Open Source Securities released a research report on April 8 stating that it gave Health Yuan (600380.SH) a purchase rating. The main reasons for the rating include: 1) inhaled formulations continue to rise, and revenue from the health products business h
Open Source Securities released a research report on April 8 stating that it gave Health Yuan (600380.SH) a purchase rating. The main reasons for the rating include: 1) inhaled formulations continue to rise, and revenue from the health products business has increased significantly; 2) leaders in inhaled formulations, the pace of innovative drugs and high-barrier formulations has accelerated. (Mainichi Keizai Shimbun)
Health Source (600380): Performance is in line with expectations; sales of inhaled formulations slightly exceeded expectations
The 2023 results are in line with our expectations. The company announced its 2023 results: revenue of 16.646 billion yuan, down 2.90% year on year; net profit to mother was 1,443 billion yuan, down 3.99% year on year, in line with our expectations.
Health Source (600380) 2023 performance review: rapid growth in inhaled formulations, expected tobramycin doses
Incident: The company released its 2023 annual report. In 2023, it achieved revenue of 16.646 billion yuan, a year-on-year decrease of 2.90%, net profit to mother of 1,443 billion yuan, a year-on-year decrease of 3.99%, after deducting 13.7 billion yuan in net profit from non-return to mother
Express News | Health yuan: It is planned to purchase steam, power, etc. up to 300 million yuan from Jinguan Electric Power
Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Sheds 6.5% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. Buying under-rated businesses is one path to excess returns. To
Express News | Health Yuan and Bayer reach exclusive licensing cooperation for small molecule inhibitors
Health Yuan (600380) Company's First Coverage Report: Inhalation Formulation Leader Starts a New Journey with Diversified Businesses
Leading inhalation formulations, continuing to focus on innovative drugs and high-barrier formulations Health Yuan Pharmaceutical Group owns two large listed companies, Health Yuan and Lizhu Pharmaceutical. The company insists on being driven by R&D innovation, focusing on innovative drugs and complex formulations with high barriers, and business coverage
Are Strong Financial Prospects The Force That Is Driving The Momentum In Joincare Pharmaceutical Group Industry Co.,Ltd.'s SHSE:600380) Stock?
Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) stock is up by a considerable 17% over the past month. Given that the market rewards strong financials in the long-term, we wonder if that i
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug
Livzon Pharmaceutical Group (HKG:1513, SHE:000513), a unit of Joincare Pharmaceutical (SHA:600380), will conduct clinical trials on JP-1366 tablets after obtaining the approval of China's National Med
Analysis
Price Target
No Data
